Clinical experience with tocilizumab in the treatment of pregnant woman with severe COVID-19

Authors

DOI:

https://doi.org/10.14739/2310-1237.2022.1.253286

Keywords:

coronavirus disease, COVID-19, infectious pregnancy complications, tocilizumab

Abstract

The aim of the work – to present a case of positive use of tocilizumab in the treatment of pregnant woman with severe COVID-19.

Materials and methods. A self-observation clinical case of severe coronavirus disease (COVID-19) in pregnant K., 40 years old, who was treated at Municipal Non-Profit Enterprise “Regional Infectious Diseases Clinical Hospital” of Zaporizhzhia Regional Council. The patient was treated in accordance with the “Protocol for the provision of medical care for the treatment of coronavirus disease (COVID-19)”.

Results. Our own clinical observation demonstrates the formation of severe COVID-19 in a 40-year-old pregnant woman in the second trimester of pregnancy. Combination treatment with glucocorticoids in the presence of oxygen dependence on the 11th day of the disease was ineffective for two days of clinical and laboratory parameters monitoring, which required a decision on the additional appointment of tocilizumab. The development of “cytokine storm” clinical and laboratory signs on the 12th day of the disease was evidenced by the preservation of fever in the range of 37.5–37.8 °C, no regression of oxygen dependence. According to laboratory data, an increase in the severity of lymphopenia as a relative quantity – up to 5 % and absolute quantity – up to 0.5 × 109/l, an increase in fibrinogen – up to 5.8 g/l and D-dimer – up to 1.9 ng/ml, high level of C-reactive protein – up to 190 mg/l. These data justify the additional use of tocilizumab, which was administered at a dose of 8 mg/kg in the absence of contraindications. Tocilizumab administration was effective, contributing to oxygen dependence regression and recovery of laboratory parameters within a week.

Conclusions. Our own clinical observation demonstrates the formation of severe COVID-19 in pregnant woman in the second trimester of pregnancy. Due to the ineffectiveness of glucocorticosteroid therapy and the presence of clear clinical and laboratory signs of “cytokine storm” on the 12th day of the disease, the use of tocilizumab was effective, which contributed to the oxygen dependence regression and recovery of laboratory parameters within a week. Treatment of pregnant woman with severe COVID-19 requires adherence to existing protocols.

Author Biographies

O. V. Riabokon, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Infectious Diseases

I. O. Kuliesh, Municipal Non-Profit Enterprise “Regional Infectious Diseases Clinical Hospital” of Zaporizhzhia Regional Council, Ukraine

MD, Director, Head of the Department No. 1

O. O. Furyk, Zaporizhzhia State Medical University, Ukraine

MD, PhD, Associate Professor of the Department of Infectious Diseases

T. B. Matvieieva, Municipal Non-Profit Enterprise “Regional Infectious Diseases Clinical Hospital” of Zaporizhzhia Regional Council, Ukraine

MD, Head of Department No. 4

K. V. Kalashnyk, Zaporizhzhia State Medical University, Ukraine

MD, PhD, Assistant of the Department of Infectious Diseases

References

Racicot, K., & Mor, G. (2017). Risks associated with viral infections during pregnancy. Journal of Clinical Investigation, 127(5), 1591-1599. https://doi.org/10.1172/jci87490

Hantoushzadeh, S., Shamshirsaz, A. A., Aleyasin, A., Seferovic, M. D., Aski, S. K., Arian, S. E., Pooransari, P., Ghotbizadeh, F., Aalipour, S., Soleimani, Z., Naemi, M., Molaei, B., Ahangari, R., Salehi, M., Oskoei, A. D., Pirozan, P., Darkhaneh, R. F., Laki, M. G., Farani, A. K., … Aagaard, K. (2020). Maternal death due to covid-19. American Journal of Obstetrics and Gynecology, 223(1). https://doi.org/10.1016/j.ajog.2020.04.030

Li, J., Wang, Y., Zeng, Y., Song, T., Pan, X., Jia, M., He, F., Hou, L., Li, B., He, S., & Chen, D. (2020). Critically ill pregnant patient with Covid-19 and neonatal death within two hours of birth. International journal of gynaecology and obstetrics, 150(1), 126-128. https://doi.org/10.1002/ijgo.13189

Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Effect of dexamethasone in hospitalized patients with COVID-19 – preliminary report. https://doi.org/10.1101/2020.06.22.20137273

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/

Ministry of Healthcare of Ukraine. (2020, April 2). Protokol "Nadannia medychnoi dopomohy dlia likuvannia koronavirusnoi khvoroby (COVID-19)" [Protocol for the provision of medical care for the treatment of coronavirus disease (COVID-19) (No. 762)]. [in Ukrainian]. https://zakon.rada.gov.ua/rada/show/v0762282-20?lang=en#Text

Tolcher, M. C., McKinney, J. R., Eppes, C. S., Muigai, D., Shamshirsaz, A., Guntupalli, K. K., & Nates, J. L. (2020). Prone positioning for pregnant women with hypoxemia due to coronavirus disease 2019 (COVID-19). Obstetrics & Gynecology, 136(2), 259-261. https://doi.org/10.1097/aog.0000000000004012

Rahmati, M. (2020). Cytokine-targeted therapy in severely ill covid-19 patients: Options and cautions. Eurasian Journal of Medicine and Oncology, 4(2), 179-180. https://doi.org/10.14744/ejmo.2020.72142

Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2015). Tocilizumab in early progressive rheumatoid arthritis: Function, a randomised controlled trial. Annals of the Rheumatic Diseases, 75(6), 1081-1091. https://doi.org/10.1136/annrheumdis-2015-207628

Furst, D. E. (2004). Anakinra: Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clinical Therapeutics, 26(12), 1960-1975. https://doi.org/10.1016/j.clinthera.2004.12.019

Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, C.-C. V., Edwards, K. M., Gandhi, R., Gallagher, J., Muller, W. J., O’Horo, J. C., Shoham, S., Murad, M. H., Mustafa, R. A., Sultan, S., & Falck-Ytter, Y. (2020). Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

National Institute for Health and Care Excellence. (2021, March 23). COVID-19 rapid guideline: managing COVID-19: Guidance NG191. NICE. https://www.nice.org.uk/guidance/ng191

Okoh, A. K., Bishburg, E., Grinberg, S., & Nagarakanti, S. (2021). Tocilizumab use in COVID-19-associated pneumonia. Journal of medical virology, 93(2), 1023-1028. https://doi.org/10.1002/jmv.26471

Lan, S.-H., Lai, C.-C., Huang, H.-T., Chang, S.-P., Lu, L.-C., & Hsueh, P.-R. (2020). Tocilizumab for severe COVID-19: A systematic review and meta-analysis. International Journal of Antimicrobial Agents, 56(3), 106103. https://doi.org/10.1016/j.ijantimicag.2020.106103

Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., Bureau, S., Dougados, M., Tibi, A., Azoulay, E., Cadranel, J., Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F., Pourchet-Martinez, V., … Renet, S. (2021). Effect of tocilizumab vs usual care in adults hospitalized with covid-19 and moderate or severe pneumonia. JAMA Internal Medicine, 181(1), 32. https://doi.org/10.1001/jamainternmed.2020.6820

Atal, S., & Fatima, Z. (2020). IL-6 inhibitors in the treatment of serious covid-19: A promising therapy? Pharmaceutical Medicine, 34(4), 223-231. https://doi.org/10.1007/s40290-020-00342-z

Riabokon, O. V., Cherkaskyi, V. V., Onishchenkо, T. Y., & Riabokon, Y. Y. (2021). Features of comorbid pathology spectrum and age structure of oxygen-dependent patients with severe coronavirus disease 2019 (COVID-19) depending on outcomes of the disease. Zaporozhye Medical Journal, 23(2), 214-219. https://doi.org/10.14739/2310-1210.2021.2.228712

Vizir, V. A., Sadomov, A. S., & Demidenko, O. V. (2021). Use of tocilizumab in the combination treatment of a COVID-19 patient with concomitant rheumatoid arthritis (a case report). Zaporozhye Medical Journal, 23(5), 739-748. https://doi.org/10.14739/2310-1210.2021.5.232322

Naqvi, M., Zakowski, P., Glucksman, L., Smithson, S., & Burwick, R. M. (2020). Tocilizumab and Remdesivir in a pregnant patient with coronavirus disease 2019 (COVID-19). Obstetrics & Gynecology, 136(5), 1025-1029. https://doi.org/10.1097/aog.0000000000004050

Wei, S.-Q., Fraser, W., & Luo, Z.-C. (2010). Inflammatory cytokines and spontaneous preterm birth in asymptomatic women. Obstetrics & Gynecology, 116(2), 393-401. https://doi.org/10.1097/aog.0b013e3181e6dbc0

Allotey, J., Stallings, E., Bonet, M., Yap, M., Chatterjee, S., Kew, T., Debenham, L., Llavall, A. C., Dixit, A., Zhou, D., Balaji, R., Lee, S. I., Qiu, X., Yuan, M., Coomar, D., Sheikh, J., Lawson, H., Ansari, K., van Wely, M., van Leeuwen, E., … for PregCOV-19 Living Systematic Review Consortium (2020). Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ (Clinical research ed.), 370, m3320. https://doi.org/10.1136/bmj.m3320

Cohen, J., Vignaux, O., & Jacquemard, F. (2020). Covid-19 in pregnant women: General Data from a French national survey. European Journal of Obstetrics & Gynecology and Reproductive Biology, 251, 267-268. https://doi.org/10.1016/j.ejogrb.2020.06.002

Khoury, R., Bernstein, P. S., Debolt, C., Stone, J., Sutton, D. M., Simpson, L. L., Limaye, M. A., Roman, A. S., Fazzari, M., Penfield, C. A., Ferrara, L., Lambert, C., Nathan, L., Wright, R., Bianco, A., Wagner, B., Goffman, D., Gyamfi-Bannerman, C., Schweizer, W. E., … Dolan, S. M. (2020). Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection at five New York City medical centers. Obstetrics & Gynecology, 136(2), 273-282. https://doi.org/10.1097/aog.0000000000004025

Pierce-Williams, R. A. M., Burd, J., Felder, L., Khoury, R., Bernstein, P. S., Avila, K., Penfield, C. A., Roman, A. S., DeBolt, C. A., Stone, J. L., Bianco, A., Kern-Goldberger, A. R., Hirshberg, A., Srinivas, S. K., Jayakumaran, J. S., Brandt, J. S., Anastasio, H., Birsner, M., O’Brien, D. S., … Berghella, V. (2020). Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: A united states cohort study. American Journal of Obstetrics & Gynecology MFM, 2(3), 100134. https://doi.org/10.1016/j.ajogmf.2020.100134

Downloads

Published

2022-04-15

How to Cite

1.
Riabokon OV, Kuliesh IO, Furyk OO, Matvieieva TB, Kalashnyk KV. Clinical experience with tocilizumab in the treatment of pregnant woman with severe COVID-19. Pathologia [Internet]. 2022Apr.15 [cited 2024Apr.16];19(1):79-83. Available from: http://pat.zsmu.edu.ua/article/view/253286

Issue

Section

Case Reports